JPM: Aridis CEO Truong on why the pandemic hasn't bolstered antibiotics R&D and what needs to change
The COVID-19 pandemic has spurred enormous interest and innovation in vaccines, antivirals and anti-infective drugs and for obvious reasons. There’s another area that might have been buoyed by the ...
ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Aridis Pharmaceuticals (NASDAQ:ARDS) on The RedChip Money Report® on Bloomberg TV, this Saturday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results